Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer

J. C. Wilson*, L. J. Murray, C. M. Hughes, A. Black, L. A. Anderson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)
2 Downloads (Pure)



Evidence for non-steroidal anti-inflammatory drugs (NSAIDs) preventing head and neck cancer (HNC) is inconclusive; however, there is some suggestion that aspirin may exert a protective effect.


Using data from the United States National Cancer Institute Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, we examined the association between aspirin and ibuprofen use and HNC.


Regular aspirin use was associated with a significant 22% reduction in HNC risk. No association was observed with regular ibuprofen use.


Aspirin may have potential as a chemopreventive agent for HNC, but further investigation is warranted.

Original languageEnglish
Pages (from-to)1178-1181
Number of pages4
JournalBritish Journal of Cancer
Issue number5
Early online date28 Feb 2013
Publication statusPublished - 19 Mar 2013


  • aspirin
  • cohort study
  • head and neck cancer
  • ibuprofen


Dive into the research topics of 'Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer'. Together they form a unique fingerprint.

Cite this